An external pilot cluster randomised controlled trial of a theory-based intervention to improve appropriate polypharmacy in older people in primary care (PolyPrime)

Audrey Rankin, Ashleigh Gorman, Judith Cole, Cathal A Cadogan, Heather E Barry, Ashley Agus, Danielle Logan, Cliona McDowell, Gerard J Molloy, Cristín Ryan, Claire Leathem, Marina Maxwell, Connie Brennan, Gerard J Gormley, Alan Ferrett, Pat McCarthy, Tom Fahey, Carmel M Hughes, PolyPrime team, Lynn Murphy, Gavin Kennedy, Catherine Adams, Laurie Martin, Joanne Thompson, Sorcha Toase, Carys Boyd, Rachael McQuillan, Máire O'Dwyer, Audrey Rankin, Ashleigh Gorman, Judith Cole, Cathal A Cadogan, Heather E Barry, Ashley Agus, Danielle Logan, Cliona McDowell, Gerard J Molloy, Cristín Ryan, Claire Leathem, Marina Maxwell, Connie Brennan, Gerard J Gormley, Alan Ferrett, Pat McCarthy, Tom Fahey, Carmel M Hughes, PolyPrime team, Lynn Murphy, Gavin Kennedy, Catherine Adams, Laurie Martin, Joanne Thompson, Sorcha Toase, Carys Boyd, Rachael McQuillan, Máire O'Dwyer

Abstract

Background: For older populations with multimorbidity, polypharmacy (use of multiple medications) is a standard practice. PolyPrime is a theory-based intervention developed to improve appropriate polypharmacy in older people in primary care. This pilot study aims to assess the feasibility of the PolyPrime intervention in primary care in Northern Ireland (NI) and the Republic of Ireland (ROI).

Methods: This external pilot cluster randomised controlled trial (cRCT) aimed to recruit 12 general practitioner (GP) practices (six in NI; six in the ROI counties that border NI) and ten older patients receiving polypharmacy (≥ 4 medications) per GP practice (n = 120). Practices allocated to the intervention arm watched an online video and scheduled medication reviews with patients on two occasions. We assessed the feasibility of collecting GP record (medication appropriateness, health service use) and patient self-reported data [health-related quality of life (HRQoL), health service use)] at baseline, 6 and 9 months. HRQoL was measured using the EuroQol-5 dimension-5 level questionnaire (EQ-5D-5L) and medication-related burden quality-of-life (MRB-QoL) tool. An embedded process evaluation and health economics analysis were also undertaken. Pre-specified progression criteria were used to determine whether to proceed to a definitive cRCT.

Results: Twelve GP practices were recruited and randomised. Three GP practices withdrew from the study due to COVID-related factors. Sixty-eight patients were recruited, with 47 (69.1%) being retained until the end of the study. GP record data were available for 47 patients for medication appropriateness analysis at 9 months. EQ-5D-5L and MRB-QoL data were available for 46 and 41 patients, respectively, at 9 months. GP record and patient self-reported health service use data were available for 47 patients at 9 months. Health service use was comparable in terms of overall cost estimated from GP record versus patient self-reported data. The intervention was successfully delivered as intended; it was acceptable to GPs, practice staff, and patients; and potential mechanisms of action have been identified. All five progression criteria were met (two 'Go', three 'Amend').

Conclusion: Despite challenges faced during the COVID-19 pandemic, this study has demonstrated that it may be feasible to conduct an intervention to improve appropriate polypharmacy in older people in primary care across two healthcare jurisdictions.

Trial registration: ISRCTN, ISRCTN41009897 . Registered 19 November 2019.

Clinicaltrials: gov, NCT04181879 . Registered 02 December 2019.

Keywords: Behaviour change; Complex intervention; General practice; Older people; Pilot study; Polypharmacy; Prescribing; Primary care; Process evaluation.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT flow diagram for the PolyPrime study. GPP, general practitioner practice; IQR, interquartile range. aThe number of patients screened for eligibility relates to 8 GPPs as information was not available for 4 GPPs. bThe number of patients contacted and consented relates to 10 GPPs as two GPPs withdrew from the study after randomisation but before baseline data collection and before any details on patient numbers could be obtained. cOne intervention arm GPP withdrew from the study, and patients did not receive any medication reviews; however, 3 patients were followed up for the patient-reported outcome questionnaires. dAn additional patient withdrew consent from study, but the primary outcome data were collected prior to withdrawal

References

    1. Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39:109–116. doi: 10.1007/s40264-015-0378-5.
    1. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:1–10. doi: 10.1186/s12916-015-0322-7.
    1. McGarrigle C, Donoghue O, Scarlett S, Kenny RA. Health and wellbeing: active ageing for older adults in Ireland. Dublin: The Irish Longitudinal Study on Ageing (TILDA): 2017. . Accessed 26 Feb 2022.
    1. Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication without harm: WHO’s third global patient safety challenge. Lancet. 2017;389:1680–1681. doi: 10.1016/S0140-6736(17)31047-4.
    1. World Health Organisation . Medication safety in polypharmacy. Geneva: World Health Organization; 2019.
    1. Duncan EM, Francis JJ, Johnston M, Davey P, Maxwell S, McKay GA, et al. Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctors. Implement Sci. 2012;7:86. doi: 10.1186/1748-5908-7-86.
    1. Mucklow J, Bollington L, Maxwell S. Assessing prescribing competence. Br J Clin Pharmacol. 2012;74:632–639. doi: 10.1111/j.1365-2125.2011.04151.x.
    1. Rankin A, Cadogan C, Ryan C, Clyne B, Smith SM, Hughes C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018;9:CD008165. doi: 10.1002/14651858.CD008165.pub4.
    1. Cadogan CA, Ryan C, Francis JJ, Gormley GJ, Passmore P, Kerse N, et al. Improving appropriate polypharmacy for older people in primary care: selecting components of an evidence-based intervention to target prescribing and dispensing. Implement Sci. 2015;10:161. doi: 10.1186/s13012-015-0349-3.
    1. Cadogan CA, Ryan C, Francis JJ, Gormley GJ, Passmore P, Kerse N, et al. Development of an intervention to improve appropriate polypharmacy in older people in primary care using a theory-based method. BMC Health Serv Res. 2016;16:661. doi: 10.1186/s12913-016-1907-3.
    1. Cadogan CA, Ryan C, Gormley GJ, Francis JJ, Passmore P, Kerse N, et al. A feasibility study of a theory-based intervention to improve appropriate polypharmacy for older people in primary care. Pilot Feasibility Stud. 2017;4:23. doi: 10.1186/s40814-017-0166-3.
    1. Gorman A, Rankin A, Barry H, Cadogan C, Gormley G, Fahey T, et al. A qualitative study to refine a theory-based intervention to improve appropriate polypharmacy in older people in primary care. Int J Pharm Pract. 2020;28(S1):12.
    1. Rankin A, Cadogan CA, Barry HE, Gardner E, Agus A, Molloy GJ, et al. An external pilot cluster randomised controlled trial of a theory-based intervention to improve appropriate polypharmacy in older people in primary care (PolyPrime): study protocol. Pilot Feasibility Stud. 2021;7:77. doi: 10.1186/s40814-021-00822-2.
    1. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Ann Behav Med. 2013;46:81–95. doi: 10.1007/s12160-013-9486-6.
    1. Lewis T. Using the NO TEARS tool for medication review. BMJ. 2004;329(7463):434. doi: 10.1136/bmj.329.7463.434.
    1. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–218. doi: 10.1093/ageing/afu145.
    1. National Institute for Health and Care Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes [NG5]. 2015. . Accessed 18 Feb 2022.
    1. Health Service Executive (HSE). Chronic Disease Management Programme: 2020 . Accessed 28 Feb 2022.
    1. Rankin A, Molloy GJ, Cadogan CA, Barry HE, Gorman A, Ryan C, et al. Protocol for a process evaluation of an external pilot cluster randomised controlled trial of a theory-based intervention to improve appropriate polypharmacy in older people in primary care: the PolyPrime study. Trials. 2021;22:449. doi: 10.1186/s13063-021-05410-6.
    1. Sergeant ESG. Epitools epidemiological calculators, Ausvet: 2018. Available at: . Accessed 1 Mar 2022.
    1. Curtis L, Burns A. Unit Costs of Health and Social Care 2020. Personal Social Services Research Unit, University of Kent, Canterbury: 2020. . Accessed 25 Feb 2022.
    1. Department of Health. Reference Costs 2019-20, Department of Health: 2020.
    1. Smith S, Jiang J, Normand C, O’Neill C. Unit costs for non-acute care in Ireland 2016-2019 [version 1; peer review: 1 approved] HRB Open Res. 2021;4:39. doi: 10.12688/hrbopenres.13256.1.
    1. Healthcare Pricing Office. ABF Admitted Patient Price List 2019, Healthcare Pricing Office: 2019. . Accessed 25 Feb 2022.
    1. Organisation for Economic Cooperation and Development (OECD). Purchasing power parities (PPP) (indicator): 2022. 10.1787/1290ee5a-en. Accessed 25 Feb 2022.
    1. Heslin M, Babalola O, Ibrahim F, Stringer D, Scott D, Patel A. A comparison of different approaches for costing medication use in an economic evaluation. Value Health. 2018;21:185–192. doi: 10.1016/j.jval.2017.02.001.
    1. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727–1736. doi: 10.1007/s11136-011-9903-x.
    1. Mohammed MA, Moles RJ, Hilmer SN, O’Donnel LK, Chen TF. Development and validation of an instrument for measuring the burden of medicine on functioning and well-being: the medication-related burden quality of life (MRB-QoL) tool. BMJ Open. 2018;8:e018880. doi: 10.1136/bmjopen-2017-018880.
    1. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708–715. doi: 10.1016/j.jval.2012.02.008.
    1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [PMG9]. 2013. . Accessed 25 Feb 2022.
    1. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17:1–3. doi: 10.1186/s12913-017-2031-8.
    1. Carey RN, Connell LE, Johnston M, Rothman AJ, de Bruin M, Kelly MP, et al. Behavior change techniques and their mechanisms of action: a synthesis of links described in published intervention literature. Ann Behav Med. 2019;53:693–707.
    1. Borrelli B, Sepinwall D, Ernst D, Bellg AJ, Czajkowski S, Breger R, et al. A new tool to assess treatment fidelity and evaluation of treatment fidelity across 10 years of health behavior research. J Consult Clin Psychol. 2005;73:852–860. doi: 10.1037/0022-006X.73.5.852.
    1. Lancaster GA, Thabane L. Guidelines for reporting non-randomised pilot and feasibility studies. Pilot Feasibility Stud. 2019;5:114. doi: 10.1186/s40814-019-0499-1.
    1. Clyne B, Smith SM, Hughes CM, Boland F, Bradley MC, Cooper JA, et al. Effectiveness of a multifaceted intervention for potentially inappropriate prescribing in older patients in primary care: a cluster-randomized controlled trial (OPTI-SCRIPT study) Ann Fam Med. 2015;13:545–553. doi: 10.1370/afm.1838.
    1. Thornton J. Covid-19: how coronavirus will change the face of general practice forever. BMJ. 2020;368:m1279. doi: 10.1136/bmj.m1279.
    1. Shiely F, Foley J, Stone A, Cobbe E, Browne S, Murphy E, Kelsey M, Walsh-Crowley J, Eustace JA. Managing clinical trials during COVID-19: experience from a clinical research facility. Trials. 2021;22:1–7. doi: 10.1186/s13063-020-05004-8.
    1. Rankin A, Cadogan CA, Ryan C, Clyne B, Smith SM, Hughes CM. Core outcome set for trials aimed at improving the appropriateness of polypharmacy in older people in primary care. JAGS. 2018;66:1206–1212. doi: 10.1111/jgs.15245.
    1. Fraser C, Fisher R. How has the COVID-19 pandemic impacted primary care? Health Foundation. 2021. . Accessed 28 Mar 2022.
    1. Abraham C, Wood CE, Johnston M, Francis J, Hardeman W, Richardson M, Michie S. Reliability of identification of behavior change techniques in intervention descriptions. Ann Behav Med. 2015;49:885–900. doi: 10.1007/s12160-015-9727-y.
    1. Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37. doi: 10.1186/1748-5908-7-37.
    1. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. doi: 10.1136/bmj.a1655.
    1. Medical Research Council. Developing and evaluating complex interventions: new guidance: 2008. . Accessed 24 Feb 2022.
    1. Thornton J. Clinical trials suspended in UK to prioritise covid-19 studies and free up staff. BMJ. 2020;368:m1172. doi: 10.1136/bmj.m1172.

Source: PubMed

3
订阅